Cinven Completes Final Realisation of Medpace

August 24, 2018

International private equity firm Cinven has completed the final sell down of its remaining shares in Nasdaq-listed Medpace, realising its investment from the Fifth Cinven Fund. Medpace, a Cincinnati-based global contract research organisation (CRO), expanded internationally and grew its workforce substantially under Cinven's ownership before its August 2016 IPO and subsequent sell downs, with the final sell down achieved at a significant premium to the IPO price.

Buyers
Various public market investors
Targets
Medpace
Sellers
Cinven, Fifth Cinven Fund
Location
Ohio, United States
Transaction Type
Divestiture

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.